CN119031942A - 基因表达调控剂、阿尔茨海默症的预防药或治疗药和痴呆的改善方法 - Google Patents

基因表达调控剂、阿尔茨海默症的预防药或治疗药和痴呆的改善方法 Download PDF

Info

Publication number
CN119031942A
CN119031942A CN202380027002.7A CN202380027002A CN119031942A CN 119031942 A CN119031942 A CN 119031942A CN 202380027002 A CN202380027002 A CN 202380027002A CN 119031942 A CN119031942 A CN 119031942A
Authority
CN
China
Prior art keywords
hsa
mir
gene expression
gene
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380027002.7A
Other languages
English (en)
Chinese (zh)
Inventor
古贺祥嗣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dexon Pharmaceuticals Inc
Original Assignee
Dexon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dexon Pharmaceuticals Inc filed Critical Dexon Pharmaceuticals Inc
Publication of CN119031942A publication Critical patent/CN119031942A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380027002.7A 2022-03-22 2023-03-19 基因表达调控剂、阿尔茨海默症的预防药或治疗药和痴呆的改善方法 Pending CN119031942A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022044972A JP7492757B2 (ja) 2022-03-22 2022-03-22 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
JP2022-044972 2022-03-22
PCT/JP2023/010775 WO2023182243A1 (ja) 2022-03-22 2023-03-19 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法

Publications (1)

Publication Number Publication Date
CN119031942A true CN119031942A (zh) 2024-11-26

Family

ID=88100891

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380027002.7A Pending CN119031942A (zh) 2022-03-22 2023-03-19 基因表达调控剂、阿尔茨海默症的预防药或治疗药和痴呆的改善方法

Country Status (5)

Country Link
US (1) US20250195554A1 (https=)
EP (1) EP4497445A1 (https=)
JP (1) JP7492757B2 (https=)
CN (1) CN119031942A (https=)
WO (1) WO2023182243A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119193819A (zh) * 2024-11-28 2024-12-27 苏州麦锐克生物科技有限公司 用于阿尔茨海默病诊断的多重miRNA标志物及试剂盒

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2025170079A1 (https=) * 2024-02-09 2025-08-14
CN118236389B (zh) * 2024-05-28 2024-09-24 南京晖丽生物科技有限公司 miR-3120在制备预防及治疗肿瘤及肿瘤恶液质的药物组合物中的应用
CN119185350B (zh) * 2024-08-15 2025-09-09 安徽农业大学 靶向lrp6的抑制剂在调节动物剩余采食量中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011118795A1 (ja) 2010-03-26 2013-07-04 国立大学法人名古屋大学 損傷部治療用組成物
JP2017184642A (ja) 2016-04-01 2017-10-12 株式会社ヘルシーパス 認知症マーカー、それを用いた認知症の評価方法、評価試薬および評価キット
JP2018023343A (ja) 2016-08-12 2018-02-15 国立大学法人山口大学 細胞培養用培地、及び細胞培養方法
IL264825B (en) 2016-08-14 2022-08-01 Univ Ramot Mesenchymal cell-derived exosomes to treat neurological disorders
US12233092B2 (en) 2018-04-10 2025-02-25 Brainstorm Cell Therapeutics Ltd. MSC-NTF specific exosomes and use thereof
AU2020299633B2 (en) * 2019-07-02 2026-03-26 Ohio State Innovation Foundation Neurodegenerative disease therapies utilizing the skin-brain axis
US20210002650A1 (en) * 2019-07-03 2021-01-07 University Of Virginia Patent Foundation Compositions and methods for treating alzheimer's disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119193819A (zh) * 2024-11-28 2024-12-27 苏州麦锐克生物科技有限公司 用于阿尔茨海默病诊断的多重miRNA标志物及试剂盒

Also Published As

Publication number Publication date
JP2023139438A (ja) 2023-10-04
WO2023182243A1 (ja) 2023-09-28
US20250195554A1 (en) 2025-06-19
JP7492757B2 (ja) 2024-05-30
EP4497445A1 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
CN119031942A (zh) 基因表达调控剂、阿尔茨海默症的预防药或治疗药和痴呆的改善方法
US20260103713A1 (en) Microparticle, agent for activating nk cell, method for culturing nk cell, method for producing activated nk cell, and method for activating nk cell
US20240424029A1 (en) Agent for improving cancer cachexia and method for improving cancer cachexia
WO2023190267A1 (ja) 微小粒子、パーキンソン病の予防薬または治療薬およびパーキンソン病の改善方法
JP2024000504A (ja) Ｈｍｇｂ１の発現制御剤；急性肺損傷、急性呼吸窮迫症候群または敗血症の予防薬または治療薬、あるいはそれらの改善方法
CN116171158A (zh) 细胞因子风暴抑制剂、细胞因子风暴抑制剂的使用方法和筛选方法
WO2006041088A1 (ja) 脳移行性骨髄前駆細胞
JP2025032034A (ja) 若返り剤および若返り方法
EP4628086A1 (en) Microparticle, drug for prevention or treatment of erectile dysfunction, and erectile dysfunction improvement method
WO2023199828A1 (ja) 微小粒子、血管新生眼疾患の予防薬または治療薬および血管新生眼疾患の改善方法
JP2025172276A (ja) 遺伝子の発現制御剤、アルツハイマー病の予防薬または治療薬および認知症の改善方法
EP4541358A1 (en) Hmgb1 expression suppressor, prophylactic or therapeutic drug for acute lung injury, acute respiratory distress syndrome or sepsis, and method for ameliorating such disease
WO2023199829A1 (ja) 微小粒子、うつ病の予防薬または治療薬およびうつ病の改善方法
WO2023248845A1 (ja) Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法
WO2022014046A1 (ja) 組成物、医療機器およびｃｏｖｉｄ－１９の予防方法
US20250381230A1 (en) Methods and compositions for treatment of neurodegenerative disorders and reducing tau protein aggregates
JP2025095535A (ja) Ｐｔｘ３の発現制御剤；関節リウマチ、自己免疫疾患に伴う血管炎または皮膚硬化の予防薬または治療薬、あるいはそれらの改善方法
JP2026007350A (ja) がん微小環境の改善剤、抗腫瘍免疫応答の予防薬または治療薬およびがん微小環境の改善方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination